Sickle Cell Trait - Revision history

Ellouise.Bishop@anthonynolan.org at 16:41, 29 October 2026

2026-10-29T16:41:42Z

← Older revision		Revision as of 16:41, 29 October 2026
Line 9:		Line 9:

	==Explanation of Condition==		==Explanation of Condition==
	Sickle Cell Trait (SCT) is an inherited carrier state in which an individual carries one abnormal allele of the β-globin gene. This results in a heterozygous state consisting of sickle haemoglobin (HbS) and normal adult haemoglobin (HbA).		Sickle Cell Trait (SCT) is an inherited carrier state in which an individual carries one abnormal allele of the β-globin gene. This results in a heterozygous state consisting of sickle haemoglobin (HbS) and normal adult haemoglobin (HbA). It is present in over 300 million people worldwide. It is particularly frequent in individuals of African, Middle Eastern, Mediterranean, and Indian ancestry due to selection pressure for its protective effect against malaria. However, SCT may be present in individuals of any ethnic background.

	It is present in over 300 million people worldwide. It is particularly frequent in individuals of African, Middle Eastern, Mediterranean, and Indian ancestry due to selection pressure for its protective effect against malaria. However, SCT may be present in individuals of any ethnic background.


	Historically SCT donors were only permitted to donate via bone marrow harvest due to perceived risk of sickling within the apheresis circuit. However, a review of evidence by WMDA donor suitability committee has lead to change in guidance announced in October 2026.		Historically SCT donors were only permitted to donate via bone marrow harvest due to perceived risk of sickling within the apheresis circuit. However, a review of evidence by WMDA donor suitability committee has lead to change in guidance announced in October 2026.
	There is no evidence of clinically significant sickling or other sickle cell disease-associated with complications during or after mobilised PBSC collection or bone marrow harvest in donors with SCT.		There is no evidence of clinically significant sickling or other sickle cell disease-associated with complications during or after mobilised PBSC collection or bone marrow harvest in donors with SCT.


	Assessing donor suitability for either PBSC or bone marrow, attention should be paid to the donor’s additional risk factors for pulmonary embolism (especially a personal or close family history of venous thromboembolism), dehydration, pre-existing splenic disease, or chronic kidney disease. With individualised donor risk assessment if any of these risks are identified. As for all donors, they should be evaluated for co-morbidities, be adequately hydrated, and receive appropriate analgesia before and during, and after progenitor cell mobilisation by apheresis or bone marrow harvest.		Assessing donor suitability for either PBSC or bone marrow, attention should be paid to the donor’s additional risk factors for pulmonary embolism (especially a personal or close family history of venous thromboembolism), dehydration, pre-existing splenic disease, or chronic kidney disease. With individualised donor risk assessment if any of these risks are identified. As for all donors, they should be evaluated for co-morbidities, be adequately hydrated, and receive appropriate analgesia before and during, and after progenitor cell mobilisation by apheresis or bone marrow harvest.
Line 22:		Line 21:
	For recipients of diverse ethnicities who may have a limited choice of donors, the consequences of donor-derived SCT are outweighed by the chance of cure.		For recipients of diverse ethnicities who may have a limited choice of donors, the consequences of donor-derived SCT are outweighed by the chance of cure.

			==Guidance==
			<u>Please note this guidance applies to SCT only - Sickle cell disease (HbSS) and other variants (HbSC, HbSBthal, HbSD) are not acceptable</u>.

	~~<u>Please note this guidance applies to SCT only - Sickle cell disease (HbSS) and other variants (HbSC, HbSBthal, HbSD) are not acceptable</u>.~~

	~~==Guidance==~~
	'''At Recruitment'''		'''At Recruitment'''

Line 34:		Line 33:

	QUALIFIED		QUALIFIED


	If otherwise suitable, the donor could be ACCEPTED for mobilised PBSC collection or bone marrow harvest.		If otherwise suitable, the donor could be ACCEPTED for mobilised PBSC collection or bone marrow harvest.

Ellouise.Bishop@anthonynolan.org at 16:33, 29 October 2026

2026-10-29T16:33:51Z

← Older revision		Revision as of 16:33, 29 October 2026
Line 12:		Line 12:

	It is present in over 300 million people worldwide. It is particularly frequent in individuals of African, Middle Eastern, Mediterranean, and Indian ancestry due to selection pressure for its protective effect against malaria. However, SCT may be present in individuals of any ethnic background.		It is present in over 300 million people worldwide. It is particularly frequent in individuals of African, Middle Eastern, Mediterranean, and Indian ancestry due to selection pressure for its protective effect against malaria. However, SCT may be present in individuals of any ethnic background.


	Historically SCT donors were only permitted to donate via bone marrow harvest due to perceived risk of sickling within the apheresis circuit. However, a review of evidence by WMDA donor suitability committee has lead to change in guidance announced in October 2026.		Historically SCT donors were only permitted to donate via bone marrow harvest due to perceived risk of sickling within the apheresis circuit. However, a review of evidence by WMDA donor suitability committee has lead to change in guidance announced in October 2026.
Line 17:		Line 18:

	Assessing donor suitability for either PBSC or bone marrow, attention should be paid to the donor’s additional risk factors for pulmonary embolism (especially a personal or close family history of venous thromboembolism), dehydration, pre-existing splenic disease, or chronic kidney disease. With individualised donor risk assessment if any of these risks are identified. As for all donors, they should be evaluated for co-morbidities, be adequately hydrated, and receive appropriate analgesia before and during, and after progenitor cell mobilisation by apheresis or bone marrow harvest.		Assessing donor suitability for either PBSC or bone marrow, attention should be paid to the donor’s additional risk factors for pulmonary embolism (especially a personal or close family history of venous thromboembolism), dehydration, pre-existing splenic disease, or chronic kidney disease. With individualised donor risk assessment if any of these risks are identified. As for all donors, they should be evaluated for co-morbidities, be adequately hydrated, and receive appropriate analgesia before and during, and after progenitor cell mobilisation by apheresis or bone marrow harvest.


	For recipients of diverse ethnicities who may have a limited choice of donors, the consequences of donor-derived SCT are outweighed by the chance of cure.		For recipients of diverse ethnicities who may have a limited choice of donors, the consequences of donor-derived SCT are outweighed by the chance of cure.


	<u>Please note this guidance applies to SCT only - Sickle cell disease (HbSS) and other variants (HbSC, HbSBthal, HbSD) are not acceptable</u>.		<u>Please note this guidance applies to SCT only - Sickle cell disease (HbSS) and other variants (HbSC, HbSBthal, HbSD) are not acceptable</u>.

Ellouise.Bishop@anthonynolan.org at 16:33, 29 October 2026

2026-10-29T16:33:18Z

← Older revision		Revision as of 16:33, 29 October 2026
Line 20:		Line 20:
	For recipients of diverse ethnicities who may have a limited choice of donors, the consequences of donor-derived SCT are outweighed by the chance of cure.		For recipients of diverse ethnicities who may have a limited choice of donors, the consequences of donor-derived SCT are outweighed by the chance of cure.

	<u>Please note this guidance applies to SCT only - Sickle cell disease (HbSS) and other variants (HbSC, HbSBthal, HbSD) are not acceptable.<u/>		<u>Please note this guidance applies to SCT only - Sickle cell disease (HbSS) and other variants (HbSC, HbSBthal, HbSD) are not acceptable</u>.

	==Guidance==		==Guidance==
Line 34:		Line 34:

	If otherwise suitable, the donor could be ACCEPTED for mobilised PBSC collection or bone marrow harvest.		If otherwise suitable, the donor could be ACCEPTED for mobilised PBSC collection or bone marrow harvest.

			''Attention should be paid to the donor’s additional risk factors for pulmonary embolism (especially that of a personal or close family history of venous thromboembolism) or for chronic kidney disease.''

	Transplant centre should be informed about donor SCT prior to transplant		Transplant centre should be informed about donor SCT prior to transplant
Line 39:		Line 41:


	Guidance for CORD BLOOD DONATION		'''Guidance for CORD BLOOD DONATION'''

	May donate if either parent has SCT, but cord unit should be tested for haemoglobinopathy before banking.		May donate if either parent has SCT, but cord unit should be tested for haemoglobinopathy before banking.

	If the cord blood or infant/child is tested for the condition and is shown to have SCT, accept and inform the transplant centre.		If the cord blood or infant/child is tested for the condition and is shown to have SCT, accept and inform the transplant centre.


	==Pseudonyms or Related Conditions==		==Pseudonyms or Related Conditions==
Line 50:		Line 51:

	==Other relevant pages==		==Other relevant pages==
	Haemoglobin Disorder		[[Haemoglobin Disorder]]

	==Version==		==Version==

Ellouise.Bishop@anthonynolan.org at 16:31, 29 October 2026

2026-10-29T16:31:07Z

@@ Line 9: / Line 9: @@
 ==Explanation of Condition==
 ==Guidance==
-Currently may donate by bone marrow harvest only. Due to a perceived risk of sickling within the apheresis circuit.
+'''At Recruitment'''
 ==Pseudonyms or Related Conditions==
 Sickle Cell Carrier
 ==Version==
-Version 1, Edition 1
+Version 1, Edition 2
 ====Date of Last Update====
 th June 2012

Dr Robert Lown: Protected "Sickle Cell Trait" (‎[edit=sysop] (indefinite) ‎[move=sysop] (indefinite))

2012-06-19T13:28:06Z

Protected "Sickle Cell Trait" (‎[edit=sysop] (indefinite) ‎[move=sysop] (indefinite))

← Older revision

Revision as of 13:28, 19 June 2012

Dr Robert Lown: Page created

2012-06-14T14:43:40Z

Page created

New page

==Acceptability at Recruitment==
QUALIFIED

==Acceptability at CT / Work-Up==
QUALIFIED

==Individual at Risk==
Donor

==Explanation of Condition==

==Guidance==
Currently may donate by bone marrow harvest only. Due to a perceived risk of sickling within the apheresis circuit.

Due to shortage of donors in this ethnic group, this is the only category of donors who are currently permitted to donate by bone marrow harvest only.

==Pseudonyms or Related Conditions==
Sickle Cell Carrier

==Version==
Version 1, Edition 1

====Date of Last Update====
15th June 2012